Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients

Diabetic Medicine

Volumn 20, Issue 7, 2003, Pages 545-551

  Rosskamp, Ralf ^a  

^a SANOFI   (France)

Author keywords

HOE 901; Insulin glargine; NPH insulin; Recombinant insulin analogue; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; C PEPTIDE; FATTY ACID; FRUCTOSAMINE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SWEATING; TACHYCARDIA; TONGUE DISEASE; TREMOR; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0038336648     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00999.x     Document Type: Article

References (17)

1. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-854.
2. Galloway JA. New directions in drug development: mixtures, analogues, and modeling. Diabetes Care 1993; 16: 16-23.
3. Galloway JA, Chance RE. Improving insulin therapy: achievements and challenges. Horm Metab Res 1994; 26: 591-598.
4. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-199.
5. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
6. Grau U. Insulin-Arg2, a new retardation principle based on a natural proinsulin-derived processing intermediate. Diabetes Res Clin Pract 1985; 1: 204.
7. Jorgensen S, Vaag A, Langkjaer L, Hougaard P, Markussen J. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. Br Med J 1989; 299: 415-419.
8. Zeuzem S, Stahl E, Jungmann E, Zoltobrocki M, Schoffling K, Caspary WF. In vitro activity of biosynthetic human diarginylinsulin. Diabetologia 1990; 33: 65-71.
9. Monti LD, Poma R, Caumo A, Stefani I, Picardi A, Sandoli EP et al. Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metabolism 1992; 41: 540-544.
10. Hilgenfeld R, Dorschug M, Geisen K, Neubauer H, Overmeier R, Seipke G et al. Controlling insulin bioavailability by crystal contact engineering. Diabetologia 1992; 35: A193.
11. Seipke G, Geisen K, Neubauer H-P, Pittius C, Rosskamp R, Schwabe D. New insulin preparations with prolonged action profiles: A21-modified arginine insulins. Diabetologia 1992; 35: A4.
12. Seipke G, Berchthold H, Geisen K, Hilgenfeld R, Rosskamp R. HOE901: a new insulin with prolonged action. Eur J Endocrinol 1995; 132: 25.
13. Coates PA, Mukherjee S, Luzio S, Srodzinski KA, Kurzhals R, Rosskamp R et al. Pharmacokinetics of a 'long-acting' human insulin analogue (HOE901) in healthy subjects. Diabetes 1995; 44: 130A.
14. Talaulicar M, Willms B, Rosskamp R. Efficacy of HOE 901 following subcutaneous injection for four days in type 1 diabetic subjects. Diabetologia 1995; 37: A169.
15. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000; 23: 157-162.
16. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
17. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.